This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ursin, G. Articles by Spicer, D. V. Search for Related Content PubMed PubMed Citation Articles by Ursin, G. Articles by Spicer, D. V.

Mammographic Density Changes During the Menstrual Cycle

Departments of Preventive Medicine [G. U., M. C. P.], Radiology [Y. R. P.], and Medicine [D. V. S.], University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90089

The ability to detect small tumors is impaired in dense mammograms. It has been suggested that the sensitivity of mammograms could be lower in mammograms obtained during the luteal phase of the menstrual cycle. We examined the change in mammographic density from the follicular to the luteal phase of the menstrual cycle in 11 women. Although the average increase in densities was quite small (1.2%; P = 0.08), six women had clinically significant increases (1.4–7.8%), suggesting that premenopausal women should undergo mammographic examinations in the follicular part of the menstrual cycle

This article has been cited by other articles:

				K. M. Blackmore, J. A. Knight, and L. Lilge Association between Transillumination Breast Spectroscopy and Quantitative Mammographic Features of the Breast Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1043 - 1050. [Abstract] [Full Text] [PDF]

				J. E. Olson, C. X. Ma, L. L. Pelleymounter, D. J. Schaid, V. S. Pankratz, R. A. Vierkant, Z. S. Fredericksen, J. N. Ingle, Y. Wu, F. Couch, et al. A Comprehensive Examination of CYP19 Variation and Breast Density Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 623 - 625. [Full Text] [PDF]

				J. N. Weitzel, S. S. Buys, W. H. Sherman, A. M. Daniels, G. Ursin, J. R. Daniels, D. J. MacDonald, K. R. Blazer, M. C. Pike, and D. V. Spicer Reduced Mammographic Density with Use of a Gonadotropin-Releasing Hormone Agonist-Based Chemoprevention Regimen in BRCA1 Carriers Clin. Cancer Res., January 15, 2007; 13(2): 654 - 658. [Abstract] [Full Text] [PDF]

				D. S.M. Buist, E. J. Aiello, D. L. Miglioretti, and E. White Mammographic Breast Density, Dense Area, and Breast Area Differences by Phase in the Menstrual Cycle. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2303 - 2306. [Abstract] [Full Text] [PDF]

				C. J. Fabian and B. F. Kimler Mammographic Density: Use in Risk Assessment and as a Biomarker in Prevention Trials J. Nutr., October 1, 2006; 136(10): 2705S - 2708S. [Full Text] [PDF]

				A. Stuedal, I. T. Gram, Y. Bremnes, H. Adlercreutz, M. B. Veierod, and G. Ursin Plasma Levels of Enterolactone and Percentage Mammographic Density among Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2154 - 2159. [Abstract] [Full Text] [PDF]

				G. S. Dite, J. D. Wark, G. G. Giles, D. R. English, M. R.E. McCredie, and J. L. Hopper Is There Overlap Between the Genetic Determinants of Mammographic Density and Bone Mineral Density? Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2266 - 2268. [Abstract] [Full Text] [PDF]

				A.-S. Furberg, G. Jasienska, N. Bjurstam, P. A. Torjesen, A. Emaus, S. F. Lipson, P. T. Ellison, and I. Thune Metabolic and Hormonal Profiles: HDL Cholesterol as a Plausible Biomarker of Breast Cancer Risk. The Norwegian EBBA Study Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 33 - 40. [Abstract] [Full Text] [PDF]

				G. Maskarinec, Y. Takata, A. A. Franke, A. E. Williams, and S. P. Murphy A 2-Year Soy Intervention in Premenopausal Women Does Not Change Mammographic Densities J. Nutr., November 1, 2004; 134(11): 3089 - 3094. [Abstract] [Full Text] [PDF]

				J. A. Harvey and V. E. Bovbjerg Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk Radiology, January 1, 2004; 230(1): 29 - 41. [Abstract] [Full Text] [PDF]

				C. J. Fabian, B. F. Kimler, D. A. Brady, M. S. Mayo, C. H. J. Chang, J. A. Ferraro, C. M. Zalles, A. L. Stanton, S. Masood, W. E. Grizzle, et al. A Phase II Breast Cancer Chemoprevention Trial of Oral {alpha}-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers Clin. Cancer Res., October 1, 2002; 8(10): 3105 - 3117. [Abstract] [Full Text] [PDF]

				I. T. Gram, G. Ursin, D. V. Spicer, and M. C. Pike Reversal of Gonadotropin-releasing Hormone Agonist Induced Reductions in Mammographic Densities on Stopping Treatment Cancer Epidemiol. Biomarkers Prev., November 1, 2001; 10(11): 1117 - 1120. [Abstract] [Full Text] [PDF]